Plenty of fish [oil] in the sea, have we REDUCEd-IT to one?

Check out this episode as Dr. Dave Dixon talks about REDUCE-IT and REDUCE-IT USA.  0:00-0:41: Intro0:42-1:26: Introduction of Dr. Dave Dixon1:27-5:10: Introduction of REDUCE-IT and REDUCE-IT USA5:11-6:30: Dave’s Initial Thoughts6:31-8:21: Why not OTC fish oil or omega-3 fatty acid prescriptions?8:22-9:54: Were these patients well managed at baseline?9:55-11:15: Who should we avoid icosapent ethyl in?11:16-12:19: LabelingContinue reading “Plenty of fish [oil] in the sea, have we REDUCEd-IT to one?”

In Zac Noel we ENTRUST: Double or Nothing?

In this episode, Dr. Zac Noel helps us navigate through the ENTRUST-AF PCI trial as well as dual vs. triple antithrombotic therapy. 0:00-0:40: Intro0:41-1:42: Introduction of Dr. Zachery Noel1:43-4:35: ENTRUST-AF PCI Overview4:36-5:46: Zac’s Overall Thoughts5:47-6:33: Dual antithrombotic therapy for everyone?6:34-7:38: Patient population in ENTRUST-AF PCI7:39-9:03: Other P2Y12 inhibitors9:04-10:13: Ischemic outcomes10:14-11:18: Who should receive dual antithromboticContinue reading “In Zac Noel we ENTRUST: Double or Nothing?”

Entering the TWILIGHT Zone

Prepare to dive into the TWILIGHT trial with Dr. Craig Beavers. 0:00-0:22: Intro0:23-1:01: Introduction of Dr. Craig Beavers1:02-3:32: TWILIGHT Overview3:33-6:31: Craig’s Overall Thoughts6:32-8:39: Excluded Patients8:40-10:17: Ticagrelor Monotherapy and Ischemic Outcomes10:18-12:52: TWILIGHT and GLOBAL LEADERS12:53-14:24: Final Thoughts14:25-15:22: Closing/Craig’s Upcoming Podcast References: TWILIGHT: Mehran R, Baber U, Sharma SK, et al. Ticagrelor with or without Aspirin in High-RiskContinue reading “Entering the TWILIGHT Zone”

Been there, done that: Expert advice from parting RPDs (Part 2)

In the second of two episodes, Drs. Rob DiDomenico and Kerry Pickworth provide their expertise about PGY2 Cardiology residency training. 0:00-0:40: Intro0:41-2:46: Physical exam in the cardiology setting2:47-6:17: Importance of interpreting diagnostic tests6:18-9:02: Keeping up with literature9:03-11:29: Importance of self-reflection11:30-15:00: Final thoughts/Free time (?) References: Ng TMH, DiDomenico RJ, Ripley TL, et al. An opinionContinue reading “Been there, done that: Expert advice from parting RPDs (Part 2)”

Been there, done that: Expert advice from parting RPDs (Part 1)

In the first of two episodes, Drs. Rob DiDomenico and Kerry Pickworth provide their expertise about Midyear for prospective PGY2 Cardiology residency candidates.  0:00-0:40: Intro0:41-2:22: Introduction of Drs. Rob DiDomenico and Kerry Pickworth2:23-3:17: Overview of PGY2 Cardiology Pharmacy Resident Training Opinion Paper3:18-4:56: Rob and Kerry’s Overall Thoughts4:57-9:08: Midyear Advice/What are you looking for in aContinue reading “Been there, done that: Expert advice from parting RPDs (Part 1)”

Episode 3: How sweet it is to be an SGLT2 Inhibitor

0:00-0:46: Intro0:47-1:20: Introduction of Dr. Ted Berei1:21-2:57: DAPA-HF Overview2:58-6:12: Ted’s Overall Thoughts6:13-7:24: DAPA-HF Patient Population7:25-9:15: Sacubitril/valsartan or Dapagliflozin First?9:16-10:47: Considerations Prior to Starting SGLT2 Inhibitors10:48-12:19: SGLT2 Inhibitors and Cost12:20-14:43: Final Thoughts14:44-15:42: Closing/Introduction to Finn References:  DAPA-HF: McMurray JJ, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl JContinue reading “Episode 3: How sweet it is to be an SGLT2 Inhibitor”

Episode 2: REACT(5)ion from Steve Dunn

In this episode, we review the ISAR-REACT 5 trial and hear Dr. Steve Dunn’s thoughts about how this trial fits into P2Y12 management in patients with acute coronary syndromes.  Episode:0:00-0:40: Intro0:41-1:23: Introduction of Dr. Steve Dunn1:24-3:42: ISAR-REACT 5 Overview3:43-6:28: Steve’s Overall Thoughts6:29-7:59: Context of ISAR-REACT 58:00-9:34: Study Funding9:35-11:25: Study Discontinuation Rate11:26-12:50: Secondary Safety Outcomes12:51-15:51: FinalContinue reading “Episode 2: REACT(5)ion from Steve Dunn”

CardioScripts Upcoming Podcast Episodes

REACT(5)ion from Steve Dunn: Feeling conflicted about which P2Y12 inhibitor to use since ISAR-REACT 5 was released? Listen to Steve’s REACT(5)ion here first! How sweet it is to be an SGLT2 Inhibitor: Listen to Dr. Ted Berei’s thoughts about dapagliflozin use in patients with heart failure and reduced ejection fraction. Entering the TWILIGHT Zone: InContinue reading “CardioScripts Upcoming Podcast Episodes”

Episode 1: Heart on AFIRE, Strong Desire to Stop Aspirin

In this episode, we interview Dr. Tracy Macaulay about the AFIRE trial and hear her thoughts on the role of aspirin in patients with atrial fibrillation and stable coronary disease.  Episode:0:00-1:38: Intro1:39-2:35: Introduction of Dr. Tracy Macaulay2:36-5:19: AFIRE Trial Overview5:20-7:14: Initial Thoughts7:15-10:07: AFIRE Population and Rivaroxaban Dosing10:08-11:06: Dropping Aspirin11:07-12:11: What about other anticoagulants?12:12-13:38: Final Thoughts13:39-14:50:Continue reading “Episode 1: Heart on AFIRE, Strong Desire to Stop Aspirin”